ReviewCurrent opinion in organ transplantation2011
Therapeutic issues in the treatment of vascularized xenotransplants using gal-knockout donors in nonhuman primates.
Review in Current opinion in organ transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Production of Triple-Gene (GGTA1, B2M and CIITA)-Modified Donor Pigs for Xenotransplantation.Frontiers in veterinary science · 2022Article
- Generation of GTKO Diannan Miniature Pig Expressing Human Complementary Regulator Proteins hCD55 and hCD59 via T2A Peptide-Based Bicistronic Vectors and SCNT.Molecular biotechnology · 2018Article
- Biomimetic neural scaffolds: a crucial step towards optimal peripheral nerve regeneration.Biomaterials science · 2018Review
- Genetically Modified Pigs as Organ Donors for Xenotransplantation.Molecular biotechnology · 2017Review
- Immune modulation in xenotransplantation.Archivum immunologiae et therapiae experimentalis · 2015Review
- Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation.The Journal of thoracic and cardiovascular surgery · 2014Article
- New concepts of immune modulation in xenotransplantation.Transplantation · 2013Review
- Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status.Immunology · 2013Article
- The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation.Journal of biomedical research · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewSolid organ xenotransplantation could be the future of transplantation, but improved outcomes are required in experimental models before clinical trials are justified. This review summarizes recent advances in solid organ xenotransplantation using organs from α1,3-galactosyltransferase gene-knockout (GTKO) pigs (with or without other genetic modifications) and novel therapeutic approaches. RECENT
findingsWork on the development of genetically engineered pigs has been considerable during the past few years, with many research institutes reporting the outcomes of research. Multiple gene modifications on a GTKO background have been reported, and the results of transplantation using organs from these pigs have been published. Progress, however, has been variable, and several obstacles, for example, coagulation dysregulation, have been identified. Heterotopic pig heart xenotransplantation has been associated with graft survival up to 8 months, but kidney graft survival has not improved significantly. SUMMARY: The availability of GTKO pigs with additional genetic modifications aimed toward expression of multiple complement-regulatory proteins and/or human thromboregulatory genes, combined with novel immunosuppressive regimens, for example, the inclusion of B cell-depleting agents, should improve pig organ survival in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.